PA-BENTLEY-SYSTEMS
2.12.2021 22:03:09 CET | Business Wire | Press release
Bentley Systems, Incorporated (Nasdaq:BSY), the infrastructure engineering software company, today announced the winners of the 2021 Going Digital Awards in Infrastructure . The annual awards program recognizes the extraordinary work of Bentley software users advancing infrastructure design, construction, and operations throughout the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211202005219/en/
Sixteen independent jury panels selected the 57 finalists from nearly 300 nominations submitted by more than 230 organizations from 45 countries encompassing 19 categories. To see the Going Digital Awards in Infrastructure finalists present their projects, click here .
Bentley Systems showcased 19 Going Digital Awards in Infrastructure winners on December 2 during the 2021 Year in Infrastructure and Going Digital Awards virtual event. On the previous day at the virtual event, 22 Founders’ Honorees were recognized, representing organizations or individuals whose undertakings contribute notably to infrastructure advancement and/or environmental/social development goals.
The winners of the 2021 Going Digital Awards in Infrastructure are:
Bridges
New York State Department of Transportation
East 138th Street over the Major Deegan Expressway
New York City, New York, United States
Buildings and Campuses
Volgogradnefteproekt, LLC
High-tech Multifunctional Medical Complex
Yukki, St. Petersburg, Russia
Digital Cities
Hubei International Logistics Airport Co., Ltd., Shenzhen S.F. Taisen Holdings (Group) Co., Ltd., Airport Construction Engineering Co., Ltd.
Ezhou Huahu Airport Project
Ezhou, Hubei, China
Digital Construction
Clark Construction Group, LLC
SeaTac Airport International Arrivals Facility
Seattle, Washington, United States
Geotechnical Engineering
China Water Resources Beifang Investigation, Design and Research Co. Ltd.
Geological Survey of Water Conservancy and Hydropower Engineering
Tibet, China
Land and Site Development
Liaoning Water Conservancy and Hydropower Survey and Design Research Institute Co., Ltd.
Dongtaizi Reservoir Project
Chifeng, Inner Mongolia, China
Manufacturing
WISDRI Engineering & Research Incorporation Limited
Converter-based Continuous Casting Project of Jinnan Steel Phase II Quwo Base Capacity Reduction and Replacement Project
Quwo, Shanxi, China
Mining and Offshore Engineering
Polyus
Construction of the Blagodatnoye Mill-5
Krasnoyarsk, Krasnoyarsk Krai, Russia
Power Generation
Capital Engineering and Research Incorporation Ltd.
The World’s First 60MW Subcritical Blast Furnace Gas Power Generation Project
Changshu, Jiangsu, China
Project Delivery Information Management
Mott MacDonald Systra JV with Balfour Beatty Vinci
HS2 Phase 1 Main Civil Construction Works
London, United Kingdom
Rail and Transit
Network Rail + Jacobs
Transpennine Route Upgrade
Manchester/Leeds/York, United Kingdom
Reality Modeling
HDR
Diablo Dam Digital Twin Modeling
Whatcom County, Washington, United States
Road and Rail Asset Performance
Collins Engineers, Inc.
Stone Arch Bridge Rehabilitation
Minneapolis, Minnesota, United States
Roads and Highways
PT Hutama Karya (Persero)
Trans Sumatera Toll Road Project Section Serbelawan-Pematangsiantar
Pematangsiantar, Sumatera Utara, Indonesia
Structural Engineering
HDR and the PennFIRST Team
The Pavilion at Penn Medicine
Philadelphia, Pennsylvania, United States
Utilities and Communications
PowerChina Hubei Electric Engineering Co., Ltd.
Suixian and Guangshui 80MWp Ground-based Photovoltaic Power Project of Hubei Energy Group
Guangshui, Hubei, China
Utilities and Industrial Asset Performance
Canadian Energy Company
Asset Data Lifecycle Program
Fort McMurray, Alberta, Canada
Water and Wastewater Treatment Plants
Larson & Toubro Construction
Khatan Group of Villages Water Supply Scheme (Surface Water Treatment), UP, India
Khatan, Uttar Pradesh, India
Water, Wastewater and Stormwater Networks
Companhia Águas de Joinville (CAJ)
Contingency Plan to Ensure Supply in the Event of Drought (Joinville-Santa Catarina)
Joinville, Santa Catarina, Brazil
The students winning the Future Infrastructure Star Challenge are:
Judge’s Choice Winner
Elif Gungormus Deliismail
Mini-Modular-Plant for Digitized Sustainable Campus
Izmir Institute of Technology, Turkey
People’s Choice Winner
Rodman Raul Cordova Rodriguez
Innovative Dam and Hydroelectric Project
Pontifical Catholic University of Rio de Janeiro, Brazil
To view the project descriptions and access the images, visit the Going Digital Awards in Infrastructure webpage. Detailed descriptions of all nominated projects will be published in the print and digital versions of Bentley’s 2021 Infrastructure Yearbook in early 2022. To review the past editions of this publication, access Bentley’s Infrastructure Yearbooks .
Watch the executive sessions and the Going Digital Awards finalists’ presentations from the 2021 Year in Infrastructure and Going Digital Awards virtual event on-demand here .
# #
About Bentley Systems
Bentley Systems (Nasdaq:BSY) is the infrastructure engineering software
company. We provide innovative software to advance the world’s infrastructure – sustaining both the global economy and environment. Our industry-leading software solutions are used by professionals, and organizations of every size, for the design, construction, and operations of roads and bridges, rail and transit, water and wastewater, public works and utilities, buildings and campuses, mining, and industrial facilities. Our offerings include MicroStation
-based applications for modeling and simulation, ProjectWise
for project delivery, AssetWise
for asset and network performance, Seequent’s leading geosciences software portfolio, and the iTwin
platform for infrastructure digital twins. Bentley Systems employs more than 4,000 colleagues and generates annual revenues of more than $800 million in 172 countries.
© 2021 Bentley Systems, Incorporated. Bentley, the Bentley logo, AssetWise, iTwin, MicroStation, ProjectWise, and Seequent are either registered or unregistered trademarks or service marks of Bentley Systems, Incorporated or one of its direct or indirect wholly owned subsidiaries. All other brands and product names are trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211202005219/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom